CoChat

Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial

The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To assess the efficacy and safety of coadministration of canagliflozin (CANA) and phentermine (PHEN) compared with placebo (PBO) and CANA or PHEN monotherapies in individuals who were overweight and obese without type 2 diabetes. RESEARCH DESIGN AND METHODS: This 26-week, phase 2a, randomized, double-blind, PBO-controlled, multicenter, parallel-group study enrolled individuals who were obese or overweight without type 2 diabetes (N = 335, aged 18–65 years, BMI ≥30 to <50 kg/m2 or BMI ≥27 to <50 kg/m2 with hypertension and/or dyslipidemia). Participants were randomized (1:1:1:1) to receive PBO, CANA 300 mg, PHEN 15 mg, or coadministration of CANA 300 mg and PHEN 15 mg (CANA/PHEN) orally once daily. The primary end point was percent change in body weight from baseline to week 26; key secondary end points were the proportion of participants achieving weight loss ≥5% and change from baseline in systolic blood pressure. RESULTS: CANA/PHEN provided statistically superior weight loss from baseline versus PBO at week 26 (least squares mean difference –6.9% [95% CI –8.6 to –5.2]; P < 0.001). CANA/PHEN also provided statistically superior achievement of weight loss ≥5% and reduction in systolic blood pressure compared with PBO. CANA/PHEN was generally well tolerated, with a safety and tolerability profile consistent with that of the individual components. CONCLUSIONS: CANA/PHEN produced meaningful reductions in body weight and was generally well tolerated in individuals who were overweight or obese without type 2 diabetes. Further studies are warranted to evaluate potential use of this combination for long-term weight management.

Overview

Integrity signals

Registry

Crossref · 10.2337/dc16-2427

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

7 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 29 references

Research works printed but not linked: 1

  1. Toubro, 2012, Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces body weight mainly through loss of fat mass in subjects with type 2 diabetes, Diabetologia, 55, S313

Cited by

See all 115

Metadata

Authors
Hollander, P., Bays, H. E., Rosenstock, J., Frustaci, M. E., Fung, A., Vercruysse, F., & Erondu, N.
Affiliations
  • Baylor University Medical Center (US)
  • Louisville Metabolic and Atherosclerosis Research Center (US)
  • Dallas Diabetes Research Center (US)
  • Janssen Research & Development, LLC, Spring House, PA
  • Janssen Research & Development (United States) (US)
  • Janssen (Belgium) (BE)
Corresponding author
Hollander, Priscilla
Venue
Diabetes Care
Published
2017-03-13
Volume
40
Issue
5
Pages
632-639
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2595578651
Cited by
106
References
30
Citations by year
2026: 3 · 2025: 6 · 2024: 9 · 2023: 17 · 2022: 16 · 2021: 18 · 2020: 10 · 2019: 8 · 2018: 10 · 2017: 8
FWCI
6.87
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
Funders
Janssen Research & Development, LLC
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
canagliflozin, phentermine, combination therapy, weight loss, obesity, overweight, non-diabetic obesity, SGLT2 inhibitors, appetite suppressants, systolic blood pressure, hypertension, dyslipidemia, drug safety and tolerability
MeSH terms
Canagliflozin, Adult, Appetite Depressants, Blood Pressure, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Obesity, Phentermine, Thiophenes, Overweight

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.2337/dc16-2427
The paper
Hollander, P., Bays, H. E., Rosenstock, J., Frustaci, M. E., Fung, A., Vercruysse, F., & Erondu, N. (2017). Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial. Diabetes Care. https://doi.org/10.2337/dc16-2427

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.